GlassScriptPhysician profile
Rachel Dorr
NPI 1548811342
$1,422.13
in general payments reported to CMS, 2019-2025
19 companies · $95.79 in 2025
The $95.79 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $512 · 2022: $334 · 2023: $190 · 2024: $290 · 2025: $95.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $322.78 | 2021-2024 | |
| Novo Nordisk INC | $168.02 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Amarin Pharma, INC. | $110.63 | 2021-2022 | |
| Antares Pharma, INC. | $85.76 | 2021 | |
| Astellas Pharma US INC | $85.37 | 2021-2024 | Veozah |
| Bausch Health US, LLC | $83.67 | 2022-2023 | Aplenzin |
| Pfizer INC. | $81.03 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $79.30 | 2022 | |
| Lilly USA, LLC | $78.76 | 2021-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $60.79 | 2021-2025 | Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $60.62 | 2021-2022 | |
| Amgen INC. | $45.34 | 2023-2024 | Krystexxa, Repatha, Otezla |
| Glaxosmithkline, LLC. | $42.16 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceuticals, INC. | $35.72 | 2021 | |
| Axsome Therapeutics, INC. | $20.87 | 2025 | Auvelity |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $16.67 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $15.70 | 2025 | Neffy |
| Eisai INC. | $14.64 | 2022 | |
| Irhythm Technologies, INC. | $14.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Dorr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.